On Wednesday, EF Hutton initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) shares, a biotechnology company specializing in cancer immunotherapy. The firm issued a Buy rating with a price target of $30.00, signaling confidence in the company’s potential.
ImmunityBio's lead product, Anktiva, is at the forefront of the company's innovative approach to cancer treatment. Anktiva is a superagonist of interleukin-15 (IL-15) that activates natural killer (NK) cells and generates CD8+ memory T cells. These cells play a critical role in recognizing and destroying tumor cells, especially those that avoid immune detection by suppressing MHC molecules.
The analyst highlighted the significance of Anktiva's mechanism, which transforms non-responsive "cold" tumors into "hot" tumors that are more susceptible to immune system attack. This transformation is essential for the effectiveness of the therapy, as it increases the tumor's vulnerability to the body's natural immune responses.
While bladder cancer is currently the primary focus for Anktiva's application, EF Hutton's coverage notes the therapy's broader implications. The firm believes that Anktiva's therapeutic potential is not limited to a single type of cancer but could be extended to treat other solid tumors that are amenable to checkpoint inhibitors.
The $30.00 stock price target reflects EF Hutton's anticipation of ImmunityBio's success in advancing cancer immunotherapy. The firm's endorsement underscores the promise of Anktiva's "triangle offense" strategy in the competitive field of oncology.
In other recent news, ImmunityBio Inc. announced positive results from its QUILT 3.055 trial, demonstrating prolonged survival in patients with advanced non-small cell lung cancer (NSCLC).
The trial used ANKTIVA in combination with checkpoint inhibitors KEYTRUDA or OPDIVO and showed a median overall survival of 14.1 months in patients who had progressed on checkpoint inhibitor therapies. The company is now initiating Phase 3 trials of ANKTIVA with the same inhibitors for 1st and 2nd line NSCLC treatment.
In other recent developments, ImmunityBio re-elected nine directors at the Annual Meeting of Stockholders and approved an increase in the number of shares authorized for issuance under its 2015 Equity Incentive Plan by 19.9 million.
The company also entered an exclusive global arrangement with the Serum Institute of India to manufacture Bacillus Calmette-Guerin for use with ANKTIVA, a treatment for non-muscle invasive bladder cancer which recently received U.S. Food and Drug Administration approval.
In the financial sector, Piper Sandler maintained a Neutral rating on ImmunityBio's stock while increasing the price target following the approval of Anktiva for BCG-unresponsive NMIBC treatment. These developments contribute to ImmunityBio’s trajectory in the healthcare and financial sectors.
InvestingPro Insights
ImmunityBio's innovative approach to cancer treatment has caught the attention of investors and analysts alike. According to InvestingPro data, the company's market capitalization stands at $2.43 billion, reflecting significant investor interest in its potential. This valuation comes despite the company's current financial position, with InvestingPro Tips indicating that ImmunityBio is "quickly burning through cash" and "not profitable over the last twelve months."
However, there are positive signals as well. An InvestingPro Tip notes that "analysts anticipate sales growth in the current year," which aligns with the optimistic outlook presented in EF Hutton's coverage. This expectation is supported by the company's impressive revenue growth, with InvestingPro data showing a staggering 2453.66% quarterly revenue growth in Q2 2024.
The biotechnology sector is known for its high-risk, high-reward nature, and ImmunityBio seems to fit this profile. Another InvestingPro Tip reveals that the stock has seen a "high return over the last year," with data showing a 144.06% price total return over the past year. This performance suggests that investors are betting on the company's long-term potential, possibly driven by the promise of Anktiva and its broader applications in cancer treatment.
For investors seeking a deeper understanding of ImmunityBio's prospects, InvestingPro offers 10 additional tips that could provide valuable insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.